cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Novo Nordisk's next-gen obesity drug

Inflammatory monocyte gene expression: trait or state marker in bipolar disorder

Cardiovascular effects and reduced blood flow Mounjaro can lower blood pressure, which is beneficial for heart health, but this means our body may send less blood to our hands and feet

"Intranasal delivery of biologics to the central nervous system." Advanced Drug Delivery Reviews , 64(7), 614-628

By improving insulin sensitivity, semaglutide reduces the ovarian stimulation that drives excess androgen production, potentially supporting more regular menstrual cycles and reducing hirsutism and acne

cAMP accumulation assay Peptide or small molecules stimulated cAMP accumulation was measured by a LANCE Ultra cAMP kit (PerkinElmer)

Rodrigues et al., 2016)